Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report

被引:6
作者
Hamilton, Juliette E. [1 ]
Alexander, Michael [2 ]
Kelleher, Fergal C. [1 ]
机构
[1] St James Hosp, Dept Med Oncol, Trinity Coll Dublin, Dublin 8, Ireland
[2] Tallaght Univ Hosp, Dept Neurophysiol, Dublin, Ireland
关键词
Ifosfamide; Encephalopathy; Methylene blue; Frontal rhythmic intermittent delta activity FIRDA; PREVENTION; THIAMINE;
D O I
10.1186/s13569-020-00147-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Encephalopathy is an established side effect of the chemotherapeutic agent, ifosfamide, occurring in 10-30% of cases. The EEG commonly shows non-specific features of encephalopathy, and rarely shows frontal intermittent rhythmic delta activity (FIRDA). Case presentation This is a case report of a 71 year old woman with pleomorphic sarcoma, who developed ifosfamide-induced encephalopathy with her second dose of ifosfamide. It shows the characteristic EEG findings that have been described previously with ifosfamide-induced encephalopathy and additionally the unusual and rare finding of FIRDA. This was followed up by a further EEG showing resolution of the encephalopathy, after administration of methylene blue, coinciding with rapid and complete resolution of her symptoms. Conclusion The rapid resolution of the encephalopathy on the EEG after administration of methylene blue adds further evidence to its effectiveness as a treatment for the disorder.
引用
收藏
页数:4
相关论文
共 10 条
[1]   Frontal Intermittent Rhythmic Delta Activity (FIRDA) in the Neurological Intensive Care: Prevalence, Determinants, and Clinical Significance [J].
Dericioglu, Nese ;
Khasiyev, Farid ;
Arsava, E. Murat ;
Topcuoglu, M. Akif .
CLINICAL EEG AND NEUROSCIENCE, 2018, 49 (04) :272-277
[2]   Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy [J].
Gharaibeh, Eyad Z. ;
Telfah, Mohammad ;
Powers, Benjamin C. ;
Salacz, Michael E. .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) :1784-1786
[3]  
Ginimuge Prashant R, 2010, J Anaesthesiol Clin Pharmacol, V26, P517
[4]   Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy [J].
Gusdon, Aaron M. ;
Malani, Rachna ;
Chen, Xi .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2019, 36 (02) :150-154
[5]  
Kataria PS, 2017, J PHARMACOL PHARMACO, V8, P38, DOI 10.4103/jpp.JPP_182_16
[6]  
Liu YL, 2010, TAIWAN J OBSTET GYNE, V49, P77, DOI 10.1016/S1028-4559(10)60014-9
[7]   Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis [J].
Lo, Yin ;
Shen, Li-Jiuan ;
Chen, Wen-Hwei ;
Dong, Yaa-Hui ;
Wu, Fe-Lin Lin .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2016, 115 (09) :744-751
[8]   Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy:: report of 12 cases and a review of the literature [J].
Pelgrims, J ;
De Vos, F ;
Van den Brande, J ;
Schrijvers, D ;
Prové, A ;
Vermorken, JB .
BRITISH JOURNAL OF CANCER, 2000, 82 (02) :291-294
[9]  
Richards Ashley, 2011, J Oncol Pharm Pract, V17, P372, DOI 10.1177/1078155210385159
[10]   Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant? [J].
Sejourne, Alice ;
Noal, Sabine ;
Boone, Mathieu ;
Bihan, Celine ;
Sassier, Marion ;
Andrejak, Michel ;
Chauffert, Bruno .
CASE REPORTS IN ONCOLOGY, 2014, 7 (03) :669-672